ABOUT THE GROUP

Quashie Research group is a subunit of the Virology laboratory at WACCBIP. The group aims to understand and therapeutically target key replicative processes in viruses of pandemic concern.

Dr. Peter Kojo Quashie, a Senior Research Fellow and a specialist in Molecular Virology, Viral Enzymology, Antiviral Therapeutics and Antimicrobial Drug mechanism and resistance, leads the research group. His previous research has spanned the areas of mechanistic enzymology, HIV drug resistance mechanisms, antiviral drug discovery and structural biology of viral proteins.

The research agenda of the group focuses on the following themes:

• Molecular epidemiology of HIV in West Africa, the impact and effectiveness of new antiretroviral regimen;
• Molecular epidemiology and Host:virus interactions of SARS-CoV-2, the causative agent of COVID-19;
• Antiviral targeting of viral replication and Host-virus interactions; and
• Antiviral drug development platforms for rapid and effective prioritizing of promising antiviral candidates which have already been pre-screened by other research groups.

Dr. Quashie coordinates much of WACCBIP’s SARS-CoV-2 research initiatives spanning molecular and seroepidemiology studies, host:virus interactions and drug discovery.

Dr. Peter Kojo Quashie welcomes all interested inquiries from highly motivated budding scientists about research opportunities in his group. He also welcomes opportunities for collaborative endeavours.

The Group currently has active collaborative partnerships with the Crick African Network and the Noguchi Memorial Institute for Medical Research.